Overall Survival Advantage

PROVENGE delivered a statistically significant overall survival advantage — nearly 38% more patients were still alive 3 years post-treatment in the PROVENGE group compared to control

  • Median overall survival in clinical trials was 25.8 months with PROVENGE (n=341) vs 21.7 months with control (n=171); P =0.032 (95% CI: 0.614, 0.979)
Overall survival benefit of PROVENGE1,2
Overall Survival Benefit for PROVENGE

*(Percent PROVENGE–percent control)/percent control.

PERCENTAGE OF PATIENTS ALIVE: ITT* POPULATION (95% CI)
Percentage of Patients Alive: ITT Population (95% CI)

PROVENGE provided a survival benefit every year studied

*ITT=Intent to Treat